Maintaining investigator blinding in RCTs, especially when dealing with subcutaneous and intramuscular injections of investigational medicinal products (IMP), can be challenging.Discrepancies in the appearance and viscosity of active and placebo injections have posed a hurdle. Our study compared the performance of A-INJ (specifically, the Autoject 2) against conventional syringes (CS) for delivering 1 ml doses of both placebo and reference IMP.

The results demonstrated:

- No statistically significant differences in injectate delivery between A-INJ and CS.

- Investigators were largely unable to differentiate between the two solutions when using A-INJ, effectively maintaining blinding.

This suggested that A-INJ systems offer a promising solution for RCTs, eliminating the need to modify placebos with additives or colorants, or to utilise costly unblinded staff. These findings add to the growing body of evidence highlighting the advantages of A-INJs in administering injectable compounds during RCTs, opening up new possibilities for their utility in clinical research.

Latest news

How Does Social Time Contribute to a Positive Workplace Culture?

March 13, 2023
Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.
Read more

Employee Well-Being: A Commitment that Defines Richmond

October 2, 2023
Dr. Junko Ono, the Occupational Support Manager at Richmond Pharmacology provides her insights on fostering a positive work environment.
Read more


ISA Symposium 2024

29-30 May 2024 
We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota
View event